Umbilical cord-derived stem cells (ModulatistTM) show strong immunomodulation capacity compared to adipose tissue-derived or bone marrow-derived mesenchymal stem cells

Abstract

Abstract-Introduction:Mesenchymal stem cells (MSCs) show great promise in regenerative medicine. Clinical applications of MSCs have recently increased significantly, especially for immune diseases. Autologous transplantation is considered a safe therapy. However, its main disadvantages are poor stability and quality of MSCs from patient to patient, and labor-intensive and time-consuming culture procedures. Therefore, allogeneic MSC transplantation has recently emerged as a potential replacement for autologous transplantation. "Off the shelf" MSC products, or socalled "stem cell drugs", have rapidly developed; these products have already been approved in various countries, including Canada, Korea and Japan. This study aims to evaluate a new stem cell product or "drug", termed Modulatist TM , derived from umbilical cord mesenchymal stem cells (UCMSCs), which have strong immunomodulatory properties, compared to bone marrow-derived MSCs (BMMSCs) or adipose tissue-derived stem cells (ADSCs). Methods: Modulatist TM was produced from MSCs derived from whole umbilical cord (UC) tissue (which includes Wharton's jelly and UC), according to GMP compliant procedures. Bone marrow-and adipose tissue-derived MSCs were isolated and proliferated in standard conditions, according to GMP compliant procedures. Immunomodulation mediated by MSCs was assessed by allogenic T cell suppression and cytokine release; role of prostaglandin E2 in the immunomodulation was also evaluated. Results: The results showed that Modulatist TM exhibited stronger immunomodulation than BMMSC and ADSC in vitro. Modulatist TM strongly suppressed allogeneic T cells proliferation and decreased cytokine production, compared to BMMSCs and ADSCs. Conclusion: Modulatist TM is a strong immunomodulator and promising MSC product. It may be useful to modulate or treat autoimmune diseases.

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

“…The MSC karyotyping was normal (data not shown). The MSC potency was reported previously [60]. The UC-MSCs collected via our protocols exhibited stronger immunomodulation than that of adipose-derived and bone marrow-derived MSCs.…”

“…In contrast to BM-MSCs, umbilical cord-derived MSCs (UC-MSCs) exhibit strong modulation capacity, and under the same conditions, we found that UC-MSCs more strongly inhibited allogeneic lymphocytes than did BM-MSCs or adipose tissue-derived mesenchymal stem cells [60][61][62]. UC-MSCs also have higher proliferation rates, are more primitive than are BM-MSCs [63,64], and exhibit better potential to differentiate into other cells [63][64][65][66].…”

“…In contrast to these clinical trials, UC-MSC transplantation significantly improved the quality of life and clinical conditions of COPD patients, possibly due to the strong immunomodulation capacity of the UC-MSCs compared with that of BM-MSCs reported in some publications [60,70]. This may be due to the antiinflammatory effects of UC-MSCs, which are stronger immunomodulatory cells than are MSCs from adipose tissue or bone marrow [60].…”

“…This may be due to the antiinflammatory effects of UC-MSCs, which are stronger immunomodulatory cells than are MSCs from adipose tissue or bone marrow [60]. These cells effectively inhibited the T cells, B cells, and NK cells via various mechanisms [60,[71][72][73].…”

Engineered cartilage tissue from biodegradable Poly(ε-caprolactone) scaffold and human umbilical cord derived mesenchymal stem cells

“…The frozen UCMSCs were produced by our Institute as previously published (Van Pham et al, 2016a;Van Pham et al, 2016b). The frozen UCMSCs were thawed at 37 o C for 1-2 minutes and then centrifuged at 1000 rpm for 5 minutes to eliminate the cryopreservation medium.…”